Donenberg Phillip B. 4

What Happened

• Phillip B. Donenberg, a director of Sensei Biotherapeutics (SNSE), was granted a derivative award for 1,900 shares (reported at $0.00) on February 13, 2026. The transaction was reported on a Form 4 filed February 17, 2026. This was a grant/award (not a purchase or sale), so it represents awarded equity compensation rather than an open‑market investment.

Key Details

• Transaction date: 2026-02-13; Filing date: 2026-02-17.
• Transaction type: Award/Grant of derivative securities (code A); 1,900 shares acquired at $0.00 (no cash paid reported).
• Vesting: The award vests and becomes exercisable in 36 equal monthly installments over three years, fully vesting on February 13, 2029, subject to continuous service (see footnote).
• Shares owned after the transaction: Not specified in the summary provided — see the full Form 4 for total beneficial ownership.
• No immediate exercise or sale reported in this filing.

Context

• This filing records an equity award (derivative/option-like instrument) that vests over time. Such grants are common as director or executive compensation and do not by themselves indicate buying or selling sentiment in the market. Because the award is not exercised or sold here, there was no immediate change in tradable shares.